Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07120997 · ClinicalTrials.gov registry record · NA
Prunes Preventing Bone Loss in Perimenopause
A NA study of Perimenopausal Bone Loss, sponsored by Penn State University.
- Recruiting
- Registry status
- NA
- Development phase
- 124
- Enrollment target
- 1
- Study location
NCT07120997: Recruiting NA study of Perimenopausal Bone Loss, sponsored by Penn State University.
NCT07120997 is a NA study of Perimenopausal Bone Loss that is actively recruiting participants, run by Penn State University. The registered enrollment target is 124 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07120997, a NA study of Perimenopausal Bone Loss, is actively recruiting participants, sponsored by Penn State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 124 participants
- Enrollment target
- 1
- Study location
Study Summary
Dietary interventions of prune consumption during the transmenopausal period are innovative methods to prevent bone loss. Modern medicine does not intervene to prevent or attenuate this highly vulnerable period of bone loss which, if successfully attenuated, can potentially prevent/delay osteoporosis in women. The transmenopausal period represents an opportunistic window for the study because bone loss is at its greatest at this time, with females losing as much as 6-7% of bone. If this project is successful at attenuating bone loss, it can immediately be disseminated to the public to promote prune consumption to slow down and attenuate perimenopausal bone loss. As such, this project could improve the long-term bone health of females and avoid or delay osteoporosis and improve quality of life. The long-term goal of this study is to test the novel hypothesis that prune consumption for 18 months during the 3-year transmenopausal period prevents the dramatic rate of bone loss in perimenopausal females during a window of heightened physiological vulnerability. At Penn State University, the study will compare the effects of 18 months of daily dietary consumption of 50 g of prunes (5-6) versus a no-prune control group on bone outcomes (bone mineral density, bone geometry), mechanistic factors (bone and inflammatory markers, inflammatory response of ex vivo cultured peripheral blood mononuclear cells, monocytes), and gut microbiome.
Primary Outcome
Percent change in areal bone mineral density measured at baseline, month 9, and month 18 of the 18-week dietary intervention at the lumbar spine, total hip, and femoral neck.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Prunes
- DIETARY_SUPPLEMENT Calcium supplement
- DIETARY_SUPPLEMENT Vitamin D Supplement
Study Locations (1)
Pennsylvania
- Women's Health and Exercise Laboratory, The Pennsylvania State University - University Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2025-12-11 |
| Est. Completion | 2029-12 |
| Phase | NA |
What NCT07120997 shows while recruiting
NCT07120997 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Perimenopausal Bone Loss appearing as the primary indexed condition, and to 3 interventions - of which Prunes is the first listed.
NCT07120997 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07120997 about?
NCT07120997 is a clinical study titled "Prunes Preventing Bone Loss in Perimenopause". Dietary interventions of prune consumption during the transmenopausal period are innovative methods to prevent bone loss. Modern medicine does not intervene to prevent or attenuate this highly vulnerable period of bone loss which, if successfully attenuated, can potentially prevent/delay osteoporosi...
What is the current status of trial NCT07120997?
This trial is currently recruiting. It is a NA study. The enrollment target is 124 participants. The study started on 2025-12-11. Estimated completion is 2029-12.
What conditions does trial NCT07120997 study?
This clinical trial studies the following conditions: Perimenopausal Bone Loss.
What interventions are being tested in trial NCT07120997?
The interventions under investigation include: Prunes (DIETARY_SUPPLEMENT), Calcium supplement (DIETARY_SUPPLEMENT), Vitamin D Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07120997?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07120997 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07120997's enrollment target sits among peer trials
124 758th of 2000 higher than 1,239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI